目的：探讨 CT 引导下经皮穿刺125 I 粒子永久植入治疗老年原发性非小细胞肺癌的近期疗效和安全性。方法选取经组织病理学或细胞学检查确诊、年龄>65岁、因各种原因不能手术或拒绝其他治疗、愿接受125 I粒子永久植入的原发非小细胞肺癌（NSCLC）患者59例，CT 引导下经皮穿刺125 I 粒子永久植入，术前、术中及术后进行组织多肽特异抗原（TPS）验证。患者的近期疗效采用实体瘤的治疗效果评价标准（RECIST）评价，生活质量采用 Karnofsky 评分进行评价。结果59例可评价疗效的患者中，完全缓解率为8.5%（5/59），部分缓解率为83.1%（49/59），稳定率为5.1%（3/59），进展率为3.4%（2/59）；患者6个月生存率及1年生存率分别为98.3%（58/59）、86.4%（51/59）；治疗总有效率为91.5%，临床受益率为96.6%。结论 CT 引导下经皮穿刺125 I 粒子永久植入治疗老年原发非小细胞肺癌的患者的近期疗效明显提高且安全性好。%Objective To study the short-term curative effect and security of percutaneous implan-tion of iodine-125 seeds by CT-guided puncture in treating aging primary non-small-cell lung carcinoma. Methods Fifty-nine patients who were diagnosed by histopathology or cytology were selected randomly as subjects. They were treated by percutaneous implantion iodine-125 seeds by CT-guided puncture,and vali-dated at preoperative,intraoperative and after operation. Then the short-term curative effects were evalua-ted by the standard of solid tumor,and quality of life by Karnofsky. Results CR rate was 8. 5%(5 / 59), PR rate was 83. 1%(49 / 59),SD rate was 5. 1%(3 / 59),PD rate was 3. 4%(2 / 59);six-month survival rate was 98. 3%(58 / 59),one-year survival rate was 86. 4%(51 / 59);effective power was 91. 5% . Con-clusions Percutaneous implantion of iodine-125 seeds by CT-guided puncture in treating aging primary non-small-cell lung carcinoma can improve the short-term curative effect,quality of life and is safe.
展开▼
